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We examined the ability of HIV-1 subtype C to develop resistance to the inhibitory lectins, grifﬁthsin
(GRFT), cyanovirin-N (CV-N) and scytovirin (SVN), which bind multiple mannose-rich glycans on gp120.
Four primary HIV-1 strains cultured under escalating concentrations of these lectins became increasingly
resistant tolerating 2 to 12 times their 50% inhibitory concentrations. Sequence analysis of gp120 showed
that most had deletions of 1 to 5 mannose-rich glycans. Glycosylation sites at positions 230, 234, 241, 289
located in the C2 region and 339, 392 and 448 in the C3-C4 region were affected. Furthermore, deletions
and insertions of up to 5 amino acids in the V4 region were observed in 3 of the 4 isolates. These data
suggest that loss of glycosylation sites on gp120 as well as rearrangement of glycans in V4 are
mechanisms involved in HIV-1 subtype C escape from GRFT, CV-N and SVN.
& 2013 Elsevier Inc. All rights reserved.Introduction
The surface of the HIV-1 envelope is populated with glycans that
play an important role in protecting neutralization sensitive epitopes,
promoting gp120 structural integrity and mediating interaction with
cellular receptors (Geijtenbeek and Gringhuis, 2009; Li et al., 1993;
Lin et al., 2003; Liu et al., 2004; Losman et al., 2001; Lue et al., 2002;
Wei et al., 2003; Zhu et al., 2000). The majority of glycans on the HIV-
1 envelope trimer are mannose-rich comprising 7 to 9 terminal
mannose residues (Bonomelli et al., 2011; Doores et al., 2010)
although the precise number and location remains undetermined.
Complex glycans with terminal sialic acid residues are likely also
present (Leonard et al., 1990). Mannose-rich glycans are targets for
lectins or carbohydrate binding agents (CBAs) such as grifﬁthsin
(GRFT), cyanovirin-N (CV-N) and scytovirin (SVN) isolated from
naturally occurring algae (Bokesch et al., 2003; Boyd et al., 1997;
Mori et al., 2005; Moulaei et al., 2007; Ziolkowska and Wlodawer,
2006). These lectins show potent and broad anti-HIV-1 activitiesll rights reserved.
, National Institute
Bag X4, Sandringham 2131,in vitro and are, therefore, being investigated for use in HIV-1
prevention, mostly in the form of microbicides (Balzarini, 2005;
Ferir et al., 2012; O′Keefe et al., 2009; Tsai et al., 2003, 2004).
Since the neutralization activity of lectins involves interaction
with glycans, one potential mechanism of HIV-1 escape from these
compounds is the deletion of glycosylation sites. Indeed studies on
HIV-1 subtype B have shown deletion of mannose-rich glycans is a
mechanism of resistance to CV-N (Balzarini et al., 2006; Hu et al.,
2007). More speciﬁcally, a loss of mannose-rich glycans at positions
230, 289, 295, 332, 339, 386, 392 and 448 was associated with
resistance in the laboratory-adapted strains HIV-1IIIB and HIV-1NL-4.3
(Balzarini et al., 2006). In another study, the deletion of these glycans
excluding those at positions 230 and 386 in HIV-1IIIB cultured under
escalating concentrations of CV-N, resulted in resistance to the lectin
(Hu et al., 2007). In addition, HIV-1 resistance to the lectins Galanthus
nivalis agglutinin and Hippeastrum hybrid agglutinin, was reported to
occur via a partial loss of glycans on the envelope (Balzarini et al.,
2004, 2005). Resistance to the broadly neutralizing antibody 2G12,
that targets glycans on gp120, also involves the deletion of mannose-
rich glycans. This is supported by the fact that most subtype C viruses
are resistant to this antibody due to their lack of the 295 glycosyla-
tion site (Binley et al., 2004; Chen et al., 2005; Gray et al., 2007;
Manrique et al., 2007).
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differs from subtype B (Zhang et al., 2004), and the ability of these
viruses to develop resistance to lectins is unknown. In the current
study we describe the mechanism of resistance to CV-N among
four subtype C primary viruses, which while similar to subtype B
showed some differences. This involved the deletion of mannose-
rich glycans on gp120 as well as 4–5 amino acids deletions or
insertions in the V4 region. In addition, we studied HIV-1 escape
from two other lectins, GRFT and SVN, and showed that it followed
a similar pathway to CV-N although patterns varied between the
lectins. Thus, changes of glycosylated and non-glycosylated amino
acid sequences suggest multiple mechanisms of escape from these
three lectins.Results
Replication of HIV-1 subtype C isolates in the presence
of sub-inhibitory concentrations GRFT, CV-N and SVN
HIV-1 subtype B has previously been shown to develop
resistance after repeated passages in the presence of escalating
concentrations of CV-N (Balzarini et al., 2004, 2005; Hu et al.,
2007; Witvrouw et al., 2005). Since the glycosylation pattern of
HIV-1 envelope differs by subtype (Zhang et al., 2004), we
determined the ability of viruses from subtype C to develop
resistance to CV-N and two other lectins, GRFT and SVN. Four
subtype C primary isolates were cultured in CD8 depleted PBMC in
the presence of increasing lectin concentrations for 11 to 22
weeks, starting with the concentration equal to the IC50 for each
compound (Table 1). Viral growth was measured weekly by p24
antigen ELISA. When the p24 levels in the lectin-containing
cultures were lower than the control cultures (containing no
lectin), the lectin concentrations were reduced in order to facilitate
ongoing replication (Fig. 1). Of all four isolates, Du179 showed the
highest levels of resistance, tolerating at least 10 times the starting
concentration of each lectin (Table 1). The other 3 viruses, Du151,
Du422 and COT9 grew at 3 times the starting concentrations of
GRFT and SVN and 5 times the starting concentration of CV-N.
Altogether, these data showed that the continuous growth of these
four HIV-1 subtype C viruses under lectin selective pressure
resulted in their ability to tolerate higher concentrations suggest-
ing a level of resistance to these compounds.
Lectin-selected isolates showed decreased sensitivity
and cross-resistance
We next determined whether viruses cultured in the presence of
GRFT, CV-N and SVN showed reduced sensitivity to these compounds
in the PBMC neutralization assay, using an 80% neutralization (IC80)
cut-off (Bures et al., 2002; Fenyo et al., 2009). Du179/GRFT.R, Du179/
CV-N.R and Du179/SVN.R showed at least 5-fold increase in IC80
compared to the control viruses, passaged in the absence of the lectin
(Fig. 2A). For Du151 and Du422 there was an increase in IC80 thatTable 1
IC50 values of GRFT, CV-N and SVN for the neutralization of HIV-1 isolates.
Virus Pre-selectionaIC50 (nM) Fold increase after selection
GRFT CV-N SVN GRFT CV-N SVN
Du179 37.8 102.2 134.1 10 10 12
Du151 40.3 41.2 128.5 3 5 3
Du422 39.5 82.1 215.6 3 5 2
COT9 85.8 77.1 449.5 3 4 2
a 50% Inhibitory concentration.ranged from 2 to 4 fold for all 3 lectins (Fig. 2B and C), while for
COT9, the GRFT resistant virus showed a ∼2 fold increase in IC80
(Fig. 2D). However, there was no change in IC80 for COT9 cultured
under CV-N and SVN, despite the ability to grow under increased
concentrations of the two lectins.
We next investigated whether viruses that were resistant to
each compound also showed cross-resistance or decreased sensi-
tivity to the other two lectins. We used Du179 for this study as
this virus developed the greatest resistance to all three lectins.
Du179/GRFT.R that was 10 fold resistant to GRFT showed a 3 fold
increase in resistance to CV-N and SVN neutralization (Fig. 3).
A similar pattern was observed for Du179/CV-N.R and Du179/SVN.
R. These data suggest that resistance to one lectin confers cross-
resistance to the other; however resistance to the selecting agent
was always the strongest.
Resistance was associated with amino acid changes
and deletions at and around mannose-rich glycosylation sites
The full envelope sequences of both wild-type (viruses pas-
saged in the absence of the lectin) and the corresponding resistant
viruses were compared. Wild-type Du179, Du151 and COT9 each
had 10 intact mannose-rich glycosylation sites while Du422 had
nine. All four viruses lacked the 295 glycosylation site as is
common among subtype C viruses (Zhang et al., 2004). Of the 12
selected viruses (four for each lectin), nine had deletions of glycans
on gp120 with no changes in gp41 glycosylation patterns. Seven of
the 11 glycosylation sites on gp120 that have been conﬁrmed to
contain mannose-rich glycans (Leonard et al., 1990), were involved
in resistance to GRFT, CV-N and SVN (Fig. 4). Deletions of the 230,
392 and 448 glycans were observed among viruses selected by all
three lectins with the loss of the 448 glycan observed in 6 out of
the 12 selected viruses. Except for position 289, deletions at the
seven sites occurred in response to more than one lectin.
Examination of glycan changes to individual lectins showed
that the greatest number of deleted glycans was conferred by GRFT
selection (Table 2). The loss of the glycan at position 339 occurred
in three out of four GRFT selected viruses (Table 2 and Fig. 4), with
those at position 230 and 234 occurring in two. The GRFT resistant
Du179 also deleted the 442 glycan, predicted to be complex in
studies conducted with monomeric gp120 (Kwong et al., 1998;
Leonard et al., 1990). The loss of sensitivity to GRFT in Du422
restored the glycan at position 386 that was absent in the wild
type virus (Table 2). For CV-N resistant viruses, the loss of the 448
glycan was the most common, occurring in half of these viruses
(Table 2). However, we did not observe any changes in COT9 and
Du422 sequences that accompanied their increased resistance to
CV-N. Three out of four SVN selected viruses had the 448 deletion
while two out four had the 339 glycan loss (Table 2). As with GRFT,
selection with SVN restored the 386 glycan in Du422. Lastly,
similar to CV-N, COT9 resistance to SVN was not associated with
any apparent changes in glycans.
In addition to loss of glycans on gp120, we observed deletions
and insertions of amino acid sequences near and within mannose-
rich glycosylation sites located in the fourth variable (V4) region.
GRFT resistance was associated with the deletion of four amino
acids at position 400–403 and 396–399 in Du179 and COT9,
respectively (Fig. 5A and D). However, in Du422 resistance to
GRFT resulted in the insertion of ﬁve amino acids at position 398–
402 (Fig. 5C). Similarly, CV-N resistance led to the deletion of four
amino acids in Du179 at position 392–395 (Fig. 5A) that resulted in
the loss of the 392 glycan. In Du422, SVN resistance resulted in the
insertion of ﬁve amino acids at position 398–402, this was similar
to GRFT (Fig. 5C). We observed no deletions or insertions of amino
acids in Du151 under the selective pressure of any of the three
lectins. In conclusion, our data using 4 subtype C primary isolates
Fig. 1. In vitro generation of GRFT, CV-N and SVN resistant viruses. Primary HIV-1 subtype C isolates Du179 (A), Du151 (B), Du422 (C) and COT9 (D) were cultured in PBMC
under escalating concentrations of GRFT, CV-N and SVN. The concentration of each lectin was gradually increased or reduced depending on the viral growth compared to the
control cultures (containing no lectin) as determined by p24 antigen ELISA. The arrows indicate the time-point that the supernatant was collected for analysis.
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to GRFT, CV-N and SVN may frequently also involve deletion of
multiple amino acids that results in shifting of the position of
neighboring glycans.
Single genome ampliﬁcation of GRFT, CV-N and SVN resistant viruses
Since the loss of multiple glycans observed by total viral population
sequencing could be the result of a mixture of viruses carrying fewer
deletions, we performed single genome ampliﬁcations (SGA) of gp120.
We used Du179 for this experiment since it had the highest number of
glycan loss. Six to seven clones were selected for each lectin and
compared to their corresponding total population sequence.
The majority of clones from GRFT cultures had the same
4 glycans deleted as the population sequence (highlighted in
yellow) while the 393 glycan absent in the population sequence
was deleted in only 2 of the 7 clones (Fig. 6). Furthermore, all GRFT
clones had the deletion of four amino acids in V4 and most were at
position 400 to 403. For CV-N, most clones had one to twoadditional glycans deleted compared to the total population
sequence. However, similar to the population sequence, all clones
had the deletion of four amino acids in V4, although not all in the
same location. With SVN both the number and glycan deletion
pattern of isolated clones were almost identical to the total
population sequence. But unlike this sequence, one had lost the
442 glycan while two carried deletions of amino acids in V4. Lastly,
almost all GRFT, CV-N and SVN clones had GPGQ at the tip of the
V3 loop which differed from the wild-type Du179 sequence with
GPGK. Taken together, these data show that clones largely harbor
the same mutational patterns as the total population sequence
suggesting that multiple mutations on single genomes are
required to develop resistance.
GRFT, CV-N and SVN resistance affects HIV-1 sensitivity
to neutralizing antibodies
A previous study in subtype B showed that resistance to CV-N
can affect HIV-1 sensitivity to neutralizing antibodies (Hu et al.,
Fig. 2. Lectin-selected viruses showed a decreased sensitivity to GRFT, CV-N and SVN. Resistant primary HIV-1 subtype C isolates Du179 (A), Du151 (B), Du422 (C) and COT9
(D) were tested against GRFT, CV-N and SVN in a PBMC neutralization assay. The neutralization of HIV-1 infection was measured by p24 ELISA and the IC80 of the resistant
virus and the corresponding wild-type were determined by linear regression. Bars represent standard deviation of three independent experiments.
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GRFT, CV-N and SVN impacted the senstivity to gp120 antibodies
and soluble CD4 (sCD4) in the TZM-bl neutralization assay. Five
Du179 SGA-derived clones with the highest number of glycan
deletions selected by each lectin, were tested together with the
Du179 clone passaged without the lectins (control). All GRFT, CV-N
and SVN resistant viruses showed decreased sensitivity to b12
with 4–20 fold higher antibody concentrations required for
neutralization (Table 3). In contrast, all 5 clones showed an
increased sensitivity to VRC01 of 2–6 fold. We also observed a
moderate increase in sensitivity to sCD4, which is known to have a
similar binding site to VRC01 (Zhou et al., 2010). None of the
viruses showed changes in sensitivity to the PGT121 or PGT128
mAbs, which bind to the glycans at positions 301 and 332 on the
gp120 outer domain (Walker et al., 2011). In conclusion, our data
show that resistance to GRFT, CV-N and SVN can affect HIV-1
subtype C sensitivity to some antibodies that target gp120.
Conﬁrmation of resistance conferring mutations by site-directed
mutagenesis
To conﬁrm if the changes seen in GRFT, CV-N and SVN selected
viruses (shown in Table 2 and Fig. 5) conferred resistance to the
lectins, we introduced these changes into the corresponding wild-
type cloned envelopes by site-directed mutagenesis. This included
all changes at glycosylation sites as well as deletions and inser-
tions in V4. For Du179.14 a total of 6 rounds of site-directed
mutagenesis were necessary to produce Du179/GRFT.RM (where
RM indicates resistance generated by mutagenesis). We could not
test the CV-N associated mutations as functional viruses could not
be obtained for Du179 and Du151 and no changes were noted for
Du422 and COT9. The GRFT.RM and SVN.RM envelope clones were
tested for sensitivity to GRFT and SVN relative to their wild-type
counterparts in a TZM-bl cell neutralization assay.The effect of the combined changes in glycosylation and V4
amino acid indels associated with GRFT and SVN resistance in the
four cloned envelopes resulted in a loss of sensitivity to the lectins
as seen by an increase in IC50 values of the mutant viruses
(Table 4). For GRFT, there was a 3–4 fold decrease in sensitivity
in all 4 viruses while for SVN the effect was more pronounced. In
particular the insertion of 5 amino acids together with the loss of
2 glycans in Du422.1 resulted in a 16-fold increase in resistance to
SVN. These data suggest that the changes we observed in the HIV-
1 gp120 sequences from lectin-selected PBMC cultures were
indeed resistance-conferring mutations.Discussion
In this study we demonstrated that the continuous growth of
four HIV-1 subtype C isolates under escalating concentrations of
GRFT, CV-N and SVN resulted in reduced sensitivity to these
lectins. This was associated with the deletion of mannose-rich
glycans on gp120 and in some cases insertions or deletions of
amino acids near mannose-rich glycosylation sites. These changes
were observed in both the total population and clonal sequences
of selected viruses and were conﬁrmed to be resistance conferring
by site-directed mutagenesis of envelope clones. This study is the
ﬁrst to report the mechanism of HIV-1 subtype C resistance to
GRFT, CV-N and SVN and provides important insights into the
binding sites of these lectins on the subtype C envelope.
The association between deletions of mannose-rich glycans on
the subtype C viruses studied here and increased resistance to
GRFT, CV-N and SVN is consistent with the fact that these
compounds bind glycans on the viral envelope (Ziolkowska and
Wlodawer, 2006). It also supports previous reports showing that
glycan deletions mediate HIV-1 subtype B resistance to CV-N and
GRFT (Balzarini et al., 2006; Hu et al., 2007; Huang et al., 2011;
Fig. 3. Cross-resistance between GRFT, CV-N and SVN. Du179 virus selected by
GRFT (A), CV-N (B) and SVN (C) were tested against all three lectins in a PBMC
assay. HIV-1 neutralization was measured by p24 ELISA and the IC80 of the resistant
virus (gray bar) and the corresponding wild-type (white bar) were determined by
linear regression. Bars represent standard deviation of three independent
experiments.
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Fig. 4. Mannose-rich glycosylation sites deleted in GRFT, CV-N and SVN selected
viruses. The X-axis shows the positions of mannose-rich glycans deleted in the four
isolates under lectin selective pressure. The positions of glycans are numbered
according to the HxB2 virus (Leonard et al., 1990) and were identiﬁed by sequence
analysis. The Y-axis shows the number of resistant viruses (out of 4) that had the
deletion.
K.B. Alexandre et al. / Virology 446 (2013) 66–7670Witvrouw et al., 2005). Deleted glycans were located in C2, C3, V4
and C4 suggesting that the binding sites for these lectins are
located in these regions, which are exposed on gp120 and hence
readily accessible for binding. While the most resistant viruses
generally had more glycan deletions there was no clear correlation
between the number of deleted mannose-rich glycans and resis-
tance to GRFT, CV-N and SVN. This supports our earlier study
showing that the position of the glycan is also important in
determining sensitivity to these lectins (Alexandre et al., 2010).
The lack of correlation between the number of deleted glycans and
resistance may suggest that some glycans are directly involved in
lectin binding to HIV-1 while for others the involvement may be
indirect i.e. they contribute to the formation of the binding site.
Viruses selected by the three lectins showed cross-resistance to
these compounds, also supporting our earlier ﬁnding that these
lectins have overlapping binding sites on the viral envelope. Some
of the affected glycans are within structural proximity of each
other on gp120, which together with the symmetricalarrangement of binding sites on CV-N and GRFT, suggests that
cross-linking of glycans underlies the mechanism of action of
lectin inhibition (Ziolkowska et al., 2006; Ziolkowska and
Wlodawer, 2006). This hypothesis has previously been proposed
for GRFT (Moulaei et al., 2010).
The 448 glycan was the most frequently deleted glycan sug-
gesting that it plays an important role in GRFT, CV-N and SVN
binding to subtype C gp120. This glycan together with those at
positions 230 and 392 were involved in resistance to all 3 lectins
and have previously been shown to be important for subtype B
viruses (Balzarini et al., 2006). Despite these similarities, our data
suggest that there may be subtype-speciﬁc pathways to resistance.
For example, the 332 glycan was not affected in our study while it
was lost in subtype B viruses that developed resistance to CV-N
(Balzarini et al., 2006; Hu et al., 2007; Witvrouw et al., 2005). This
being said, the differences in culture conditions in addition to the
use of different viral isolates may have accounted for some of
these subtype-speciﬁc effects. We previously showed that viruses
naturally lacking the 234 and 295 glycosylation sites were less
sensitive to GRFT, CV-N and SVN (Alexandre et al., 2010). In the
current study, we observed the deletion of the 234 glycosylation
site for two of the three lectins suggesting that this glycan can
participate in both natural and in vitro induced resistance to these
compounds. In some Du179 resistant viruses we observed the
deletion of the 442 glycosylation site which is not mannose-rich
on monomeric gp120 (Leonard et al., 1990). However, recent
studies have indicated that glycans on envelope trimer are more
resistant to mannose-trimming generating complex glycans
(Bonomelli et al., 2011; Doores et al., 2010). Thus, it can be
speculated that the 442 glycosylation site on the trimer contains
a mannose-rich glycan and is, therefore, another potential binding
site for GRFT, CV-N and SVN.
In addition to single amino acid changes that resulted in the
loss of glycans, we noted 4–5 amino acid indels in V4 sequences in
3 of the 4 viruses studied. In the case of Du179 cultured in CV-N,
this obliterated the 393 glycosylation site. This mechanism of
resistance has also been reported by Witvrouw and colleagues
who showed that HIV-1 cultured in increasing concentrations of
CV-N had a 13 amino acid deletion in V4 resulting in the loss of
3 glycosylation sites (Witvrouw et al., 2005). The other indels
found in our study did not involve the loss of glycans but occurred
near mannose-rich glycosylation sites, which likely affected their
arrangement. Further work is needed to explore the impact of
these V4 changes to determine if they affect lectin sensitivity
independently of glycan deletions.
Table 2
Changes in gp120 mannose-rich glycosylation patterns associated with resistance to GRFT, CV-N and SVN.
Lectin Virus
230 234 241 262 289 295 332 339 386
b 
392 448
GRFT Du179
Du151
Du422
COT9
CV-N Du179
Du151
Du422
COT9
SVN Du179
Du151
Du422
COT9
a Mannose-rich glycosylation sites were identified from the amino acid sequence of each envelope clone (related to HxB2) based on a study using monomeric  
  gp120 (Leonard et al., 1990).
  Red colored boxes indicate glycosylation sites that were deleted under GRFT, CV-N or SVN selective pressure.
  Green colored boxes indicate glycosylation sites that were added under GRFT, CV-N or SVN selective pressure.
  Grey colored boxes indicate sites that were unchanged.
  Blank boxes indicate sites that were absent in the wild-type virus.
b Note that for Du179 and Du151 the 392 glycan is shifted to position 393 but it is placed at position 392 for simplicity. 
    
    
a 
Predicted mannose-rich glycosylation sites
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the same number of deleted glycans as the total population
sequence. This implies that resistance is not due to a swarm of
quasispecies with different mutational proﬁles but that multiple
mutations on each genome are needed for resistance to GRFT, CV-
N and SVN. However, there was variation with some clones having
slightly different glycan deletion patterns that collectively
matched the population sequence. It is possible that each clone
has different levels of sensitivity to the lectins that could coexist
provided that they have sufﬁcient resistance conferring mutations.
It can also be speculated that the presence of strains with different
levels of glycan loss is the result of differences in their mechanisms
of escape. An in-depth analysis of minority variants in Du422 and
COT9 may help to explain why no mutations were seen in the
population sequence of these viruses despite phenotypic resis-
tance to the lectins.
The increased sensitivity of GRFT, CV-N and SVN resistant
Du179 clones to VRC01 and sCD4 suggests that lectin-escape
mutations affect the exposure of the CD4 binding site (CD4bs).
However, the simultaneous decrease in sensitivity to b12 that also
targets this site indicates that these mutations differentially affect
these compounds. This is probably due to the fact that althought
they all bind the CD4bs the footprint of VRC01, b12 and sCD4 on
gp120 do not completely overlap (Li et al., 2011; Zhou et al., 2007,
2010). A previous study showed that HIV-1 escape from CV-N did
not affect sensitivity to b12 despite the fact that this isolate
became sensitive to V3 and other HIV antibodies (Hu et al.,
2007). Our ﬁnding of decreased sensitivity to b12 in 5 distinct
clones from a single isolate suggests that there are also virus
dependent effects. We did not observe a change in sensitivity to
the PGT121 and PGT128 antibodies, consistent with the fact that
the 332 glycan (Walker et al., 2011) was not deleted in our
resistant viruses (Table 2).
Du179 developed the highest level of resistance to these lectins.
It is unlikely that this was due to differences in glycosylation as the
wild-type Du179 had an identical mannose-rich glycosylationpattern as Du151 and COT9. It is also unlikely that the pre-
selection sensitivity of these viruses to GRFT, CV-N and SVN played
any role in the development of resistance to the lectins given that
they had similar IC50 values (Table 1). However, Du179 was the
only dual-tropic virus tested here (Coetzer et al., 2007; Williamson
et al., 2003). We previously showed that GRFT blocks HIV infection
by interfering with co-receptor binding (Alexandre et al., 2011).
Thus, the ability of Du179 to enter cells via both CCR5 and CXCR4
may have provided additional opportunities to escape the inhibi-
tory effects of these lectins. Indeed, our data suggest that lectin
selection did impact on viral tropism as the GPGK at the tip of the
V3 loop in Du179 was replaced with GPGQ that is characteristic of
R5 viruses (Cilliers et al., 2003; Coetzer et al., 2011). Thus, testing a
larger number of dual tropic viruses and comparing them to single
tropic viruses may reveal to what extent the R5X4 property affects
the rate at which HIV-1 develops resistance to these lectins.
The level of resistance to the lectins observed in our study was
2–12 fold, which was not as high as reported in some other studies
(Balzarini et al., 2006; Witvrouw et al., 2005). The reason for this
may be due to our use of PBMC that do not support HIV-1
replication to the same extent as cell lines used by other investi-
gators. Also our viruses were primary isolates that may have
different replication capacity or pathways to resistance compared
to lab-adapted viruses and molecular clones used in previous
studies (Balzarini et al., 2006; Hu et al., 2007; Witvrouw et al.,
2005). Partial resistance to CV-N was also reported by Balzarini
and colleagues and was shown to be associated with fewer glycan
deletions. Deﬁning these early events in the development of
resistance will help to understand the evolution of complete lectin
resistance.
GRFT, CV-N and SVN are among leading CBAs that are being
studied for use in HIV-1 prevention. However, until now much of
what was known about HIV-1 resistance to these lectins is the
result of studies conducted with subtype B viruses that have a
different glycosylation pattern compared to subtype C (Zhang
et al., 2004). Thus the current study makes an important
Fig. 5. Changes in gp120 associated with lectin selection. Position of mannose-rich glycans and amino acid sequences for Du179 (A), Du151 (B), Du422 (C) and COT9
(D) following selection by GRFT, CV-N and SVN. Glycan deletions are shown in red and the addition in green. Symbols indicate changes in response to GRFT (*), CV-N (○) and
SVN (Δ). Deletions and insertions of amino acid sequences in V4 are shown.
K.B. Alexandre et al. / Virology 446 (2013) 66–7672contribution to our understanding of the mechanism of resistance
to GRFT, CV-N and SVN in HIV-1 subtype C viruses, the main cause
of HIV infections around the world. The extensive loss of glycans
and amino acid sequence changes required for resistance to these
three lectins poses a high genetic barrier distinct from the single
glycan deletion required to confer resistance to the 2G12 mono-
clonal antibody. Thus lectins have a broader reactivity and would
be expected to target a variety of wild-type viruses compared to
antibodies that are more speciﬁc; and attempts are being made to
test these compounds in humans. Taken together, our study
supports further research in the use of GRFT, CV-N and SVN to
prevent the spread of HIV-1.Materials and methods
Viruses, cell lines, lectins and antibodies
The R5 infectious HIV-1 subtype C viruses Du151 and Du422
were isolated from acute infections while the R5X4 Du179 was
isolated from a chronic infection in South Africa (Williamson et al.,
2003); COT9 is a R5 isolate from a chronically infected pediatric
patient (Choge et al., 2006). These four primary isolates were
chosen because they are well characterized. Furthermore, Du151,
Du422 and Du179 were previously selected as HIV-1 vaccine
strains since they represented the HIV-1 subtype C epidemic
(Williamson et al., 2003). The pSG3Δenv plasmid was providedby Dr. Beatrice Hahn. The TZM-bl cell line was from the NIH
Reference and Reagent Program (Cat No 8129) and the 293T cell
line was obtained from the American Type Culture Collection.
These two cell lines were cultured in DMEM containing 10% fetal
bovine serum (FBS). Cell monolayers were disrupted at conﬂuence
by treatment with 0.25% trypsin in 1 mM EDTA. Recombinant
GRFT, CV-N and SVN were puriﬁed from E. coli at the National
Cancer Institute, MD, USA (Bokesch et al., 2003; Boyd et al., 1997;
Mori et al., 2005). The PGT and b12 antibodies were kindly
provided by Burton and Koff of the International AIDS Vaccine
Initiative. VRC01 was obtained from the Vaccine Research Center
(Bethesda, MD) while the soluble CD4 was a generous gift from
Progenics Pharmaceuticals, Inc. (Tarrytown, NY).
Selection of GRFT, CV-N and SVN resistant viruses
One thousand TCID50 of each HIV-1 subtype C infectious isolate
were grown under escalating concentrations of GRFT, CV-N and
SVN. Viruses were cultured in 2 mL of 4106 peripheral blood
mononuclear cells (PBMC), depleted of CD8+ T cells by means of
RosetteSep CD8 depletion cocktail (StemCell Technologies, Van-
couver, Canada). The starting concentrations of the lectins were
the IC50 (50% inhibitory concentration) for each virus. Cultures
without lectins were included as experimental controls. All cul-
tures were maintained in RPMI 1640 containing 20% FBS and IL-2
(0.05 μg/mL). Viruses were passaged every 7 days by transferring
500 mL of the previous culture into fresh CD8 depleted PBMC. The
V3 
V4 
V3 
V4 
V3 
V4 
Fig. 6. Amino acid sequence of isolated GRFT, CV-N and SVN resistant Du179 clones. GRFT (A), CV-N (B) and SVN (C) resistant Du179 clones gp120 sequence isolated by single
genome ampliﬁcation were aligned with their respective population sequences. The gray shading shows the presence of a potential mannose-rich glycosylation site, yellow
shading indicates the site deletion while the red box shows the tip of the V3 loop (McCaffrey et al., 2004). Note that the glycan at position 393 is labeled as 392 in the text for
comparison with other viruses.
Table 3
Sensitivity of Du179 lectin-resistant clones to neutralizing antibodies and sCD4.
Envelope Entry inhibitors aIC50 (μg/mL) b(fold change)
b12 VRC01 PGT121 PGT128 sCD4
Control 0.7 0.60 0.065 0.18 4.0
GRFT clone 1 12.5 (18↓) 0.14 (4↑) 0.043 0.13 1.2 (3↑)
GRFT clone 7 5.8 (8↓) 0.10 (6↑) 0.049 0.20 1.8 (2↑)
CV-N clone 1 6.4 (9↓) 0.11 (5↑) 0.055 0.21 2.2 (2↑)
CV-N clone 2 13.9 (20↓) 0.15 (4↑) 0.057 0.07 1.5 (3↑)
SVN clone 2 2.6 (4↓) 0.31(2↑) 0.061 0.16 3.3
a Concentration needed to inhibit HIV-1 infection by 50%.
b Increases and decreases in sensitivity shown with arrows; only ≥2 fold
changes are shown.
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p24 antigen level in the lectin containing cultures was similar or
higher than the control cultures without lectin. When p24 levelsdropped the lectin concentration was reduced. After every passage
500 mL aliquots of culture supernatants were stored at 70 1C for
genotyping and neutralization assays.
HIV-1 neutralization assay in peripheral blood mononuclear cells
The PBMC neutralization assay was performed as described
(Bures et al., 2000). Brieﬂy, a three-fold dilution series of GRFT, CV-
N, and SVN in 40 μL of RPMI 1640 containing 20% FBS and IL-2
(growth medium) was prepared in triplicate in a U-bottom 96-well
plate. Five hundred TCID50 of the HIV-1 isolate in 15 μL of growth
medium was added to each well and the plate was incubated at
37 1C for 1 h. This was followed by the addition of 5105 cells/
well/100 mL of phytohemagglutin/IL-2 stimulated PBMC (PHA-
PBMCs). After an overnight incubation, cells were washed 3 times
with RPMI 1640 containing 20% FBS and resuspended in 155 μL of
fresh growth medium. The culture supernatant was collected
twice daily and replaced with an equal amount of fresh growth
medium. The p24 antigen concentration in the virus control wells
Table 4
Change in IC50 of mutant viruses compared to the corresponding wild type.
Pseudovirusb IC50 (nM) (fold change)a
GRFT SVN
Du179.14 (WT) 3.670.6 9.871.6
Du179/GRFT.RM (N230T/T236M/N339D/N393S/N448K/400-403 aa deletion) 13.770.6 b(↑4)
Du179/SVN.RM (N230D/N339K/N393D/N448I) 46.071.6 (↑5)
Du151.2 (WT) 3.370.2 14.070.7
Du151/GRFT.RM (N234S/S243G/S291Y ) 10.570.4 (↑3)
Du151/SVN.RM (N241K/N448D) 106.4739.2 (↑8)
Du422.1 (WT) 0.870.3 7.471.2
Du422/GRFT.RM (N230T/D386N/ 398-402 aa insertion) 3.470.8 (↑4)
Du422/SVN.RM (N339K/N448T/398-402 aa insertion) 117.5746.4 (↑16)
COT9.6 (WT) 2.770.9 21.677.5
COT9/GRFT.RM (T341I/396-399 aa deletion) 9.873.7 (↑3)
The N339I mutation was not introduced in Du151.2 since this envelope clone lacked the glycan at position 339.
a The concentration needed to inhibit HIV-1 infection by 50%. Fold change of IC50 compared to WT is shown in brackets.
b RM indicates that resistance was generated by mutagenesis. The aa changes that were introduced by mutagenesis are shown in brackets.
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Microelisa System (Biomerieux, Boseind, the Netherlands). Levels
of p24 in the lectin cultures were measured at the time-point
corresponding to the early part of the linear growth period of the
virus control (Zhou and Monteﬁori, 1997). The 80% inhibitory
concentrations (IC80) were calculated by plotting the lectin con-
centration versus the percentage inhibition in a linear regression
using GraphPad Prism 4.0 and the transformation Y¼b+mX.
HIV-1 envelope ampliﬁcation and sequencing
HIV-1 RNA was extracted from frozen culture supernatants and
reverse transcribed to cDNA using the Superscript III Reverse
Transcriptase according to the manufacturer′s instructions (Invi-
trogen, CA). For both the single genome ampliﬁcation (SGA) and
the total population ampliﬁcation, the envelope gene PCR was
carried out as described by Salazar-Gonzalez et al. (2008). The PCR
products were gel puriﬁed using the Qiagen Gel Puriﬁcation Kit
according to the manufacturer′s instruction (Hilden, Germany),
sequenced using the ABI PRISM Big Dye Terminator Cycle Sequen-
cing Ready Reaction Kit (Applied Biosystems, Foster City, CA) and
resolved on an automated genetic analyzer. Changes in the
envelopes sequences were identiﬁed using Sequencher v.4.5
(Genecodes, Ann Arbor, MI), Clustal X (ver. 1.83) and Bioedit (ver.
5.0.9).
Generation of mutants env-pseudotyped virus stock
Glycosylation sites and amino acid deletions and insertions
associated with GRFT, CV-N and SVN resistance were introduced in
HIV-1 envelope clones using the QuikChange Site Directed Muta-
genesis Kit (Stratagene, LaJolla, CA). Primers were designed to
insert or remove potential glycosylation sites and indels in a
stepwise fashion and were conﬁrmed by sequencing as described
above. HIV-1 pseudoviruses were generated by co-transfection of
the Env and pSG3Δenv plasmids (Wei et al., 2003) into 293T cells
using the Fugene transfection reagent (Roche Applied Science,
Indianapolis, IN). This was followed by the quantiﬁcation of the
TCID50 of each virus stock by infecting TZM-bl cells with serial 5-
fold dilutions of the supernatant in quadruplicate in the presence
of DEAE dextran (37.5 μg/mL) (Sigma-Aldrich, St. Louis, MO). After
48 h of culture, HIV-1 infection was measured using the Bright
Glo™ Reagent (Promega, Madison, WI), according to the manu-
facturer's instructions. Luminescence was quantiﬁed in a Wallac
1420 Victor Multilabel Counter (Perkin-Elmer, Norwalk, CT) andthe TCID50 was calculated as described elsewhere (Johnson and
Byington, 1990).
Single cycle neutralization assay (TZM-bl assay)
The pseudovirus neutralization assay was carried out as
described previously (Monteﬁori, 2004). Brieﬂy, three-fold dilu-
tion series of GRFT, CV-N and SVN in 100 μL of DMEMwith 10% FBS
(growth medium) were prepared in a 96-well plate in duplicate.
This was followed by the addition of 200 TCID50 of pseudovirus in
50 μL of growth medium and the mixture was incubated for 1 h at
37 1C. Then 100 μL of TZM-bl cells at a concentration of
1105 cells/mL in 10% FBS DMEM containing 37.5 μg/mL of DEAE
dextran was added to each well and the plate was placed at 37 1C
for 48 h. HIV-1 infection was evaluated by measuring the activity
of ﬁreﬂy luciferase. Titers were calculated as the inhibitory con-
centration that causes 50% reduction (IC50) of relative light unit
(RLU) compared to the virus control (wells with no inhibitor) after
the subtraction of the background (wells without both the virus
and the inhibitor).Acknowledgment
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